28. 全身性アミロイドーシス Systemic amyloidosis Clinical trials / Disease details
臨床試験数 : 267 / 薬物数 : 241 - (DrugBank : 77) / 標的遺伝子数 : 68 - 標的パスウェイ数 : 180
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT05066607 (ClinicalTrials.gov) | February 11, 2022 | 24/8/2021 | Isatuximab Plus Pomalidomide and Dexamethasone Association for Patients With AL Amyloidosis Not in VGPR or Better After Any Previous Therapy | A Phase 2, Open Label, Multicenter, Single-stage Study to Evaluate the Efficacy of Isatuximab Plus Pomalidomide and Dexamethasone (IPd), in Patients With AL Amyloidosis Not in VGPR or Better After Any Previous Therapy | AL Amyloidosis | Drug: Isatuximab | Intergroupe Francophone du Myelome | Sanofi;Bristol-Myers Squibb | Recruiting | 18 Years | N/A | All | 46 | Phase 2 | France |
2 | NCT01570387 (ClinicalTrials.gov) | June 2012 | 27/2/2012 | A Phase I/II Trial of Pomalidomide and Dexamethasone in Subjects With Previously-Treated AL Amyloidosis | A Phase I/II Trial of Pomalidomide and Dexamethasone in Subjects With Previously-Treated AL Amyloidosis | AL Amyloidosis | Drug: Pomalidomide;Drug: Dexamethasone | Boston Medical Center | Celgene Corporation | Completed | 18 Years | N/A | All | 27 | Phase 1/Phase 2 | United States |
3 | EUCTR2011-001787-22-IT (EUCTR) | 02/05/2012 | 12/01/2012 | Treatment with pomalidomide and dexamethasone for previously treated patients with AL amyloidosis. | An open-label, phase II study of Pomalidomide and Dexamethasone (PDex) for previously treated patients with AL amyloidosis - PDex | Previously treated AL amyloidosis MedDRA version: 14.1;Level: PT;Classification code 10002022;Term: Amyloidosis;System Organ Class: 10021428 - Immune system disorders;Therapeutic area: Diseases [C] - Blood and lymphatic diseases [C15] | Product Name: pomalidomide Product Code: CC-4047 INN or Proposed INN: Pomalidomide INN or Proposed INN: DEXAMETHASONE SODIUM SULFATE | OSPEDALE POLICLINICO S. MATTEO | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | Phase 2 | Italy | |||
4 | NCT01510613 (ClinicalTrials.gov) | February 2012 | 11/1/2012 | Pomalidomide and Dexamethasone (PDex) in AL Amyloidosis | An Open-label, Phase II Study of Pomalidomide and Dexamethasone (PDex) for Previously Treated Patients With AL Amyloidosis. | Primary Amyloidosis of Light Chain Type | Drug: Pomalidomide and Dexamethasone | IRCCS Policlinico S. Matteo | NULL | Completed | 18 Years | N/A | All | 28 | Phase 2 | Italy |